AIM ImmunoTech Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AIM American 2834 http://www.hemispherx.net/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc

AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19 - Jul 6th, 2020 1:00 pm
AIM ImmunoTech Added to Russell Microcap(R) Index - Jun 29th, 2020 10:55 am
AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020 - May 14th, 2020 10:50 am
AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference - Apr 29th, 2020 10:30 am
AIM ImmunoTech’s CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020 - Apr 20th, 2020 10:30 am
AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic - Apr 6th, 2020 10:30 pm
AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers - Apr 6th, 2020 10:30 am
AIM ImmunoTech Reports 2019 Year-end Financial Results - Mar 31st, 2020 10:45 am
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - Mar 26th, 2020 12:00 pm
AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 - Mar 9th, 2020 10:30 am
AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic - Feb 27th, 2020 11:30 am
AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic - Feb 18th, 2020 11:30 am
AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus - Feb 12th, 2020 11:30 am
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus - Feb 11th, 2020 11:30 am
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus - Feb 11th, 2020 11:30 am
AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies - Feb 5th, 2020 11:30 am
Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares - Jan 16th, 2020 10:27 am
AIM ImmunoTech to Present at the Investor Summit in Philadelphia - Dec 11th, 2019 5:20 pm